Joint Formulary & PAD

Hydrocortisone - Congenital adrenal hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Granules in capsules for opening
Associated Icons :
BNF SPC
R
Restrictions / Comments :
Important
For infants / children on doses BELOW 5mg. Capsules for opening. 0.5mg, 1mg and 2mg only. Doses of 5mg or more - to halve a 10mg tablet and use lower strength capsules to achieve correct dose. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.

Important safety information
The APC also recommend that prescribers consider the risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules (Alkindi) and note the advice for professionals included here:
https://www.gov.uk/drug-safety-update/alkindi-hydrocortisone-granules-risk-of-acute-adrenal-insufficiency-in-children-when-switching-from-hydrocortisone-tablet-formulations-to-granules

 

Status 2

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Preferred
10mg tablets can be halved for doses of 5mg. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
 

Status 3

Blue
Formulations :
  • Soluble tablets
Associated Icons :
BNF SPC
R
Restrictions / Comments :
Important
For patients on dose of 10mg AND unable to swallow solid dose forms. Requests for primary care prescribing after 1st month supply and stabilisation by specialist team.
 

Status 4

Blue
Formulations :
  • Modified release capsules
Associated Icons :
Restrictions / Comments :
Important
2nd line option. Primary Care may initiate prescribing on request from the specialist endocrinology team.
 

Status 5

Red
Formulations :
  • Oral solution
Associated Icons :
Restrictions / Comments :
Important
For use in infants and children where smaller doses are required.
 

Status 6

Non Formulary
Formulations :
  • Buccal tablets
Associated Icons :
Restrictions / Comments :
Important
(MHRA drug safety update December 2018) https://www.gov.uk/drug-safety-update/hydrocortisone-muco-adhesive-buccal-tablets-should-not-be-used-off-label-for-adrenal-insufficiency-in-children-due-to-serious-risks

PAD Profile

ChemicalSubstance :
Hydrocortisone
Indication :
Congenital adrenal hyperplasia
Group Name :
Keywords :
CAH
Brand Names Include :
Alikindi, Plenadren, Efmody
Important Information :
See PAD for guidance on providing reserve supplies for dosing during acute illness
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
6
Traffic Light Entries :
6

Other Indications

Below are listed other indications that Hydrocortisone is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Congenital adrenal hyperplasia.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) agrees the following place in therapy for glucocorticoids in line with NG243 (Adrenal insufficiency: identification and management)

  • Hydrocortidsone immediate release is the first choice glucocorticoid.
  • Prednisolone is an alternative first line if multiple daily doses are not appropriate.
  • Hydrocortisone modified-release is a 2nd line option
  • Dexamethasone is a 2nd line option
  • Fludrocortisone for mineralocorticoid replacement if needed (to normalise serum electrolytes and plasma renin, and reduce postural symptoms and salt craving)

See Formulary status and restrictions for individual formulations.

Dosing of glucocorticoids during acute illness - It is important for people with adrenal insufficiency to increase their corticosteroid doses at times of illness in order to reduce the risk of adrenal crisis. As a guide, for any moderate intercurrent illness (such as illness with fever, requiring bedrest, or requiring antibiotics), they should double their usual doses of Hydrocortisone until recovered, or if on Prednisolone, they should increase to a minimum dose of 10 mg daily (or follow specific advice as recommended by their specialist).

In order to allow patients to promptly increase their corticosteroid dose at times of need, and to avoid any risk from unexpected supply shortages, patients should ideally retain 2 months reserve supply at all times and should be reminded to renew their prescription in good time.